Biodexa Pharmaceuticals
BDRX
3 hedge funds and large institutions have $45.8K invested in Biodexa Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
200% more funds holding
Funds holding: 1 → 3 (+2)
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
0% more ownership
Funds ownership: 0% → 0% (+0%)
36% less capital invested
Capital invested by funds: $72K → $45.8K (-$26.2K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$53.6K |
| 2 |
Millennium Management
New York
|
+$35.7K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$17.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$21K |
| 2 |
VF
Virtu Financial
New York
|
-$18K |
| 3 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$11.9K |
| 4 |
KWM
Kingsview Wealth Management
Grants Pass,
Oregon
|
-$6.49K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CSS
1
Cubist Systematic Strategies
Stamford,
Connecticut
| $18.2K | +$53.6K | +3 | New |
|
|
2
Millennium Management
New York
| $14K | +$35.7K | +2 | New |
|
|
3
UBS Group
Zurich,
Switzerland
| $9.81K | +$17.9K | +1 | New |
|
|
TSS
4
Two Sigma Securities
New York
| $2.6K | – | – | – |
|
|
BBA
5
Baader Bank Aktiengesellschaft
Unterschleissheim,
Germany
| $865 | – | – | – |
|
6
RhumbLine Advisers
Boston,
Massachusetts
| $163 | – | – | – |
|
7
Morgan Stanley
New York
| $94 | – | – | – |
|
|
FDCDDQ
8
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $12 | – | – | – |
|
|
9
Renaissance Technologies
New York
| – | -$21K | -1 | Closed |
|
|
CH
10
CVI Holdings
Wilmington,
Delaware
| – | -$11.9K | – | – |
|
|
KWM
11
Kingsview Wealth Management
Grants Pass,
Oregon
| – | -$6.49K | – | – |
|
|
VF
12
Virtu Financial
New York
| – | -$18K | – | – |
|
BDRX Hedge Fund Activity: Q2 2023 in Review
3 of the 6,371 institutional investors tracked by Wall St. Rank reported a position in Biodexa Pharmaceuticals (BDRX) for Q2 2023, worth a combined $45.8K — down 36% from $72K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new BDRX positions and 1 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Cubist Systematic Strategies, opening a new position worth an estimated $53.6K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $21K sold.
- 3 institutional investors held Biodexa Pharmaceuticals (BDRX) as of Q2 2023, up from 1 in Q1 2023.
- Funds reported $45.8K of Biodexa Pharmaceuticals stock for Q2 2023, down 36% quarter-over-quarter.
- 3 funds opened new Biodexa Pharmaceuticals positions in Q2 2023 and 1 closed out, a net change of +2 holders.
- The largest Biodexa Pharmaceuticals buyer in Q2 2023 was Cubist Systematic Strategies, an estimated $53.6K added.
- The largest Biodexa Pharmaceuticals seller in Q2 2023 was Renaissance Technologies, an estimated $21K sold.
Based on aggregated 13F filings for Q2 2023.